Menard Financial Group LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,414 shares of the medical research company’s stock after selling 145 shares during the period. Menard Financial Group LLC’s holdings in Amgen were worth $588,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Folger Nolan Fleming Douglas Capital Management Inc. lifted its position in Amgen by 0.8% in the first quarter. Folger Nolan Fleming Douglas Capital Management Inc. now owns 4,986 shares of the medical research company’s stock valued at $1,241,000 after purchasing an additional 40 shares during the last quarter. Colonial Trust Advisors grew its stake in Amgen by 2.0% in the first quarter. Colonial Trust Advisors now owns 2,091 shares of the medical research company’s stock worth $520,000 after purchasing an additional 41 shares during the period. Wealth Dimensions Group Ltd. grew its stake in Amgen by 1.0% in the first quarter. Wealth Dimensions Group Ltd. now owns 3,965 shares of the medical research company’s stock worth $987,000 after purchasing an additional 41 shares during the period. Global Wealth Management Investment Advisory Inc. grew its stake in shares of Amgen by 1.8% in the first quarter. Global Wealth Management Investment Advisory Inc. now owns 2,353 shares of the medical research company’s stock worth $585,000 after acquiring an additional 41 shares during the last quarter. Finally, Miracle Mile Advisors LLC grew its stake in shares of Amgen by 4.0% in the second quarter. Miracle Mile Advisors LLC now owns 1,077 shares of the medical research company’s stock worth $262,000 after acquiring an additional 41 shares during the last quarter. 74.73% of the stock is owned by institutional investors.
A number of research analysts have weighed in on the company. Oppenheimer increased their target price on Amgen from $272.00 to $277.00 and gave the company an “outperform” rating in a report on Monday, June 7th. Robert W. Baird reiterated a “sell” rating on shares of Amgen in a report on Thursday, August 5th. Zacks Investment Research upgraded Amgen from a “sell” rating to a “hold” rating and set a $255.00 target price for the company in a report on Tuesday, June 29th. William Blair reissued a “hold” rating on shares of Amgen in a research note on Friday, September 17th. Finally, BMO Capital Markets raised their price target on Amgen from $296.00 to $301.00 and gave the stock an “outperform” rating in a research note on Monday, May 31st. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $249.70.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Monday, August 2nd. The medical research company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.09 by $0.29. The business had revenue of $6.53 billion during the quarter, compared to analyst estimates of $6.43 billion. Amgen had a return on equity of 99.85% and a net margin of 22.55%. On average, equities research analysts expect that Amgen Inc. will post 16.41 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 8th. Investors of record on Tuesday, August 17th were given a $1.76 dividend. The ex-dividend date of this dividend was Monday, August 16th. This represents a $7.04 annualized dividend and a yield of 3.27%. Amgen’s payout ratio is 42.41%.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.
Recommended Story: Quick Ratio
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.